Karyopharm shares tank after FDA insiders slam their case on the efficacy of a cancer drug with “significant toxicity”
Karyopharm’s attempt to gain an accelerated approved for selinexor as a treatment for drug-resistant cases of multiple myeloma is in serious jeopardy. And investors know it.
Their stock $KPTI plummeted 46% as analysts absorbed a highly critical assessment of their drug — an oral XPO1 inhibitor — ahead of next Tuesday’s expert panel review.
Given the history of the FDA with these kinds of reviews, Tuesday’s assessment will likely be harsh.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
